Study confirms diagnostic-grade performance of PANProfiler Breast (ER, PR, HER2) from routine brightfield images; establishing the technology as a scalable foundation for oncology across multiple canc
CAMBRIDGE, UK — April 21, 2026 — Panakeia (“the Company”), the world’s first in silico multi-omics company, today unveiled landmark pathway activation data in cancers at the American Association for
Cambridge, UK, 16 April 2026 – Panakeia (“the Company”), the world’s first in silico multi-omics company, is pleased to confirm that it will be attending and presenting at a number of conferences in